

Real world evidence of **B**empedoic Acid on **E**fficacy and **S**afety in paTients with uncontrolled LDL-c and at high risk of CVD

Abstract

Background & Objective: Cardiovascular disease (CVD) is a significant cause of morbidity and mortality worldwide, with high-risk patients requiring effective management to reduce their risk of cardiovascular events. Bempedoic acid is a novel therapeutic agent recently approved as an add-on therapy to statins in patients with uncontrolled LDL-c. Bempedoic acid inhibits cholesterol synthesis in the liver, which ultimately reduces the risk of cardiovascular events. Therefore, the present study aims to assess the efficacy and safety of bempedoic acid in patients with uncontrolled LDL-c (Previously on moderate or high-intensity statins) with a high risk of CVD in real-world settings.

Methods: This is a multicenter, retrospective observational study on the data of high-risk-CVD patients collected from **B**empedoic Acid on **E**fficacy and **S**afety in paTients (BEST) Registry. The clinical data of 140 patients who were already on statin therapy and were receiving Bempedoic acid at a dose of 180 mg, along with measurements of the level of LDL-c, HBA1c, HDL, TG, TC, PPPG, FPG, AST, ALT, serum creatinine were taken into consideration. The primary outcome includes a change in LDL-c level, and secondary outcomes involve a change in the level of HBA1c, HDL, TG, TC, PPPG, FPG, AST, ALT, and serum creatinine at week 12 and 24. Adverse events were reported at both time points.

Results: A total of 140 patients were included in the present study with a mean age of 51.8 ± 9.2 years and had primary confirmed diagnosis of dyslipidemia with uncontrolled LDL-c. The mean levels of LDL-c decreased from the mean baseline value of 142.67 ± 46.49 mg/dL, to 106.78 ± 33.92 mg/dL; a statistically significant reduction by 23.23% ($p < 0.01$) at week 12. Similarly, at week 24, the mean LDL-c value reduced to 90.39 ± 38.89 mg/dL. A 33.38 % decrease was observed ($p < 0.01$). Other parameters such as non-HDL, FPG, PPPG, AST and serum creatinine also showed statistically significant reduction at week 12 and week 24.

Conclusion: The present study demonstrates that bempedoic acid is an effective add-on medication in lowering LDL-c levels in high-risk CVD patients with uncontrolled LDL-c.

Keywords: ACL inhibitor, bempedoic acid (BA), cardiovascular diseases (CVDs), dyslipidemia, low-density lipoprotein cholesterol (LDL-c) .

Introduction

Cardiovascular diseases (CVDs) are the most significant contributor to the public health epidemic among the various chronic or non-communicable diseases prevalent in modern society. Annually 17.9 million lives are lost to CVDs and atherosclerotic cardiovascular disease (ASCVD). [1] Among the deaths caused by CVD, 85% are due to heart attack and stroke.[1] Other causes of CVD-related mortality include atherosclerosis of the aorta and peripheral vascular disease. [2] CVDs or ASCVDs are often preceded by dyslipidemia. The significant factors that lead to dyslipidemia are often associated with age and lifestyle choices.[3,4] However, dyslipidemia is not only associated with lifestyle choices, but can also stem from genetic disorders like Familial hypercholesterolemia.

The role of LDL-c in the pathogenesis of CVDs and ASCVDs has been evaluated extensively since the beginning of the twentieth century. Individuals with increased levels of low-density lipoprotein (LDL) cholesterol above 190 mg/dl are at six times greater risk of developing CVDs. [5]

Reduction of LDL-c has been associated with lowering the risk of CVDs. [6–11] Approximately 50% reduction of circulating levels of LDL-c is linked with 29% reduction in the risk of major adverse cardiovascular events.[12] The condition is often associated with changes in other biochemical markers i.e. Total Cholesterol (TC), Triglycerides (TG), High-Density cholesterol (HDL-C), non-high density cholesterol (non-HDL-c), Fasting Plasma Glucose (FPG), Post Prandial Plasma Glucose (PPPG), glycosylated

haemoglobin (HbA1c), Aspartate transaminase (AST), Alanine transaminase (ALT) and serum creatinine.[12]

Administration of statins to lower elevated levels of LDL-c have become the cornerstone of modern-day therapeutic practices aimed at reducing the risk of cardiovascular events. [13] However, it has been observed that 7 to 29% of patients receiving statin therapy have reported adverse musculoskeletal effects that severely limit their ability to receive the recommended doses.[14] Other therapies include ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors which have been shown to reduce LDL-c levels [13]

This cross-sectional study of 5888 European patients on lipid-lowering therapy found that only 54% achieved their 2016 LDL-c goal, and 33% achieved their 2019 goal. There are gaps between guideline recommendations and clinical practice, indicating a need for increased utilization of non-statin therapies for high-risk patients. [15]

Bempedoic acid (BA) is a first-in-class, novel, non-statin, oral drug which has received the US Food and Drug Administration (FDA) approval as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established ASCVD who have uncontrolled LDL-c level. [16] Administration of BA inhibits ATP citrate lyase, by targeting HMG-CoA reductase upstream in the cholesterol synthesis pathway, which increases the expression of LDL receptors, thus lowering LDL-c levels. [17,18] BA is the pro-drug form of its active component bempedoyl CoA, which gets converted by acyl-CoA synthetase-1 (ACSVL1), an enzyme whose expression is limited to the liver and kidney, thus

|

restricting BA mostly to the liver. [19] BA inhibits *de novo* lipid synthesis *in vitro* and improves serum lipid profile *in vivo via* inhibition of acetyl-CoA carboxylase (ACC) and ATP-citrate lyase, leading to the attenuation of fatty acid and sterol synthesis in the liver, respectively, leading to reduced risk of CVD among patients.

To provide better understanding on the effects of BA as add-on therapy on uncontrolled LDL-c levels among patients using statin therapy, the present study was conducted to gather real-world evidence of **Bempedoic acid** on **Efficacy** and **Safety** in patients with uncontrolled LDL-c and a high risk of CVD—the data collected from the registry which will act as a baseline for future endeavours on the topic. To the best of our knowledge, this is the first study in the Indian population that determine the efficacy and safety of BA 180 mg as an add-on therapy in patients with uncontrolled LDL-c and at high risk of CVD in real-time clinical practice.

Methods:

Study Design and Participants:

This is a multicenter, retrospective, observational study conducted on the data of dyslipidemia patients with high risk-CVD, collected from BEST Registry from July 2022 to February 2023. The clinical data of 140 dyslipidemia patients with high risk-CVD with age between 18-80 years, who were already on statin therapy and were receiving Bempedoic acid as an add-on therapy at a dosage of 180 mg, with comorbidities such as diabetes and hypertension, and uncontrolled LDL-c level as per the ESC Cholesterol Guidelines 2019. [20] Patients having total fasting triglyceride level ≥ 500 mg/dL, BMI as ≥ 50 kg/m², and severe renal impairment were excluded from the study. An ethical

waiver was given by the Institute's Ethics Committee in view of the retrospective nature of the study and all procedures being performed as a part of the routine care.

Outcome:

The primary outcome include change in LDL-c level and the secondary outcomes involve change in other biochemical markers i.e. TC, TG, HDL-c, non HDL-c, FPG, PPPG, HbA1c, AST, ALT and serum creatinine at week 12 and 24.

Safety:

Adverse events (AEs) were graded by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 and have been reported during the study.

Statistical Analysis:

The data collected were pooled in a Microsoft Excel spreadsheet and then transferred for statistical calculations to the SPSS (version 25) software. The primary and secondary endpoints was reported with two-sided 95% CIs; calculated using paired t-test. A p-value of <0.05 is considered statistically significant.

Results:

A total of 140 patients were included in the present study with a mean age of 51.8 ± 9.2 years, primary confirmed diagnosis (100%) and comorbidities such as diabetes mellitus (25%) and hypertension (24.29%). The baseline demographics have been listed in table 1.

Table 1: Baseline demographic and clinical characteristics of the study population

| Total number of patients | | 140 |
|---|--------------|----------|
| Mean age (years) | 51.8 ±9.2* | |
| Mean BMI (kg/m ²) | 28.61 ±3.25* | |
| Primary diagnosis | n | % |
| Dyslipidemia with uncontrolled LDL-c | 140 | 100 |
| Co-morbid conditions | | |
| Diabetes Mellitus | 35 | 25 |
| Hypertension | 34 | 24.29 |
| Fatty Liver / NASH | 9 | 6.43 |
| Chronic Kidney Disease | 1 | 0.71 |
| Prior history of ASCVD (MI, CAD, PAD, Stroke) | 7 | 5 |
| Hypothyroidism | 7 | 5 |
| Gout | 1 | 0.71 |
| Smoker | 2 | 1.43 |
| Heart failure | 0 | 0 |
| None | 3 | 2.14 |
| Others | 41 | 29.29 |

[**Note:** LDL-c, Low density lipid cholesterol; ASCVD, atherosclerotic cardiovascular disease; NASH, Non-Alcoholic Fatty Liver disease; MI, Myocardial Infraction; CAD, Coronary artery disease; PAD, Peripheral artery disease. * data in Mean + standard deviation (SD)]

All patients were using statins prior to BA therapy, among which 42.80% (60 of 140) were being treated with Atorvastatin (mean 40 mg), and 57.20% (80 of 140) were receiving Rosuvastatin (mean 20 mg). (Table 2)

Table 2: Ongoing medications prior to initiation of Bempedoic acid (BA) treatment

| Medication | Number of participants | % |
|-------------------------------------|-------------------------------|------------|
| Antihyperlipidemic - Statin | 140 | 100 |
| Atorvastatin (Dosage mean - 40 mg) | 60 | 42.80 |
| Rosuvastatin (Dosage mean - 20 mg) | 80 | 57.20 |
| Ezetimibe | 9 | 6.43 |
| Fenofibrate | 9 | 6.43 |
| | | |
| Antidiabetic medications | | |
| Metformin | 33 | 23.57 |
| Glimepiride | 18 | 12.86 |
| Dapagliflozin | 15 | 10.71 |
| Sitagliptin | 13 | 9.29 |
| Vildagliptin | 7 | 5 |
| Voglibose | 2 | 1.43 |
| | | |
| Antihypertensive medications | | |
| Amlodipine | 14 | 10 |
| Telmisartan | 33 | 23.57 |
| Losartan | 3 | 2.14 |
| Metoprolol | 13 | 9.29 |
| Olmesartan | 3 | 2.14 |
| Bisoprolol | 3 | 2.14 |
| | | |
| Anti-anginal drug | 14 | 10 |
| Antiplatelet medications | | |
| Ticagrelor | 18 | 12.86 |
| Clopidogrel | 6 | 4.29 |
| Aspirin | 32 | 22.86 |
| | | |

| Other Medications | | |
|----------------------|----|-------|
| Pantoprazole | 12 | 8.57 |
| Rabeprazole | 19 | 13.57 |
| Salmeterol | 3 | 2.14 |
| Torsemide | 4 | 2.86 |
| Thyroxine | 5 | 3.57 |
| Ursodeoxycholic acid | 7 | 5 |
| Vitamin E | 2 | 1.43 |

Efficacy:

The mean level of LDL-c decreased from the mean baseline value of 142.67 ± 46.49 mg/dL, to 106.78 ± 33.92 mg/dL; a statistically significant reduction by 23.23% ($p < 0.01$) at week 12 and 90.39 ± 38.89 mg/dL, 33.38 % decrease at week 24 ($p < 0.01$) was observed (Fig 1). At week 12, mean levels of TG and TC also significantly decreased by 7.64% and 14.02%, respectively ($p < 0.01$). Statistically significant reduction in the mean level of circulating concentrations was observed in the case of non-HDL (19.59%), FPG (5.9%), PPPG (3.05%), AST (10.78%) and serum creatinine (5.78%). However, an increase was observed in the case of HbA1c and ALT by 8.63% and 11.68%, respectively. On the other hand, mean levels of HDL displayed a mild increase during this period, from the mean value of 40.24 ± 8.04 mg/dL to 42.82 ± 14.37 mg/dL (Table 3)




Figure 1: Change in mean LDL-c level from baseline, at 12 weeks and at 24 weeks.

Table 3: Values of clinical parameters observed at 12 weeks, along with changes observed as compared to baseline values and corresponding p-values testing for statistical significance.

| Lab Parameters | Baseline value | | 12 weeks | | % change | p-value (12 weeks results compared with Baseline) |
|------------------------------|----------------|-------------|----------|-------------|----------|--|
| | Mean | ± Std. Dev. | Mean | ± Std. Dev. | | |
| LDL-c (mg/dL) | 142.67 | 46.49 | 106.78 | 33.92 | -23.23 | <0.01 |
| TG (mg/dL) | 251.1 | 116.09 | 210.86 | 86.47 | -7.64 | <0.01 |
| TC (mg/dL) | 227.91 | 55.88 | 192.29 | 43.85 | -14.02 | <0.01 |
| HDL(mg/dL) | 40.24 | 8.04 | 42.82 | 14.37 | +7 | 0.021 |
| Non-HDL (mg/dL) | 182.06 | 25.31 | 144.07 | 22.61 | -19.59 | <0.01 |
| FPG (mg/dL) | 121.8 | 31.41 | 117.39 | 22.74 | - 5.9 | <0.01 |
| PPPG (mg/dL) | 170.61 | 54.56 | 164.18 | 44.55 | - 3.05 | <0.01 |
| HbA1c (%) | 6.44 | 0.27 | 6.97 | 1.31 | +8.63 | <0.01 |
| AST (U/L) | 43.59 | 13.51 | 37.92 | 9.95 | -10.78 | <0.01 |
| ALT (U/L) | 34.74 | 5.43 | 37.77 | 10.13 | +11.68 | 0.001 |
| S. creatinine (mg/dL) | 0.98 | 0.24 | 0.92 | 0.25 | -5.78 | <0.01 |

[**Note:** Total Cholesterol (TC), Triglycerides (TG), High Density cholesterol (HDL-c), Non-High-Density cholesterol (non-HDL-C), Fasting Plasma Glucose (FPG), Post Prandial Plasma Glucose (PPPG), glycosylated hemoglobin (HbA1c), Aspartate transaminase (AST), Alanine transaminase (ALT)]

At the 24-week follow-up, decreasing trend from 12 weeks follow-up was sustained in the case of TG (19.67%), TC (16.21%), non-HDL (29.53%), FPG (4.8%), AST (20.69%) and serum creatinine (1.57%). An increasing trend was present in the case of HDL (10.15%) and HbA1c (4.22%) and a decrease of 16.28% was observed at the ALT level. (Table 4)

Table 4: Values of clinical parameters observed at 24 weeks, along with changes observed as compared to baseline values and corresponding *p*-values testing for statistical significance

| Lab Parameters | Baseline value | | 24 weeks | | % change | <i>p</i> -value (24 weeks results compared with Baseline) |
|------------------------------|----------------|-------------|----------|-------------|----------|---|
| | Mean | ± Std. Dev. | Mean | ± Std. Dev. | | |
| LDLc (mg/dL) | 142.67 | 46.49 | 90.39 | 38.89 | -33.38 | <0.01 |
| TG (mg/dL) | 251.1 | 116.09 | 176.13 | 49 | -19.67 | <0.01 |
| TC (mg/dL) | 227.91 | 55.88 | 185.88 | 42.1 | -16.21 | <0.01 |
| HDL (mg/dL) | 40.24 | 8.04 | 43.66 | 6.15 | +10.15 | <0.01 |
| Non-HDL (mg/dL) | 182.06 | 25.31 | 125.8 | 16.83 | -29.53 | <0.01 |
| FPG (mg/dL) | 121.8 | 31.41 | 114.24 | 19.53 | -7.96 | <0.01 |
| PPPG (mg/dL) | 170.61 | 54.56 | 157.87 | 34.29 | -4.8 | <0.01 |
| HbA1c (%) | 6.44 | 0.27 | 6.7 | 0.68 | +4.22 | <0.01 |
| AST (U/L) | 43.59 | 13.51 | 28.49 | 3.65 | -20.69 | <0.01 |
| ALT (U/L) | 34.74 | 5.43 | 28.53 | 4.05 | -16.28 | <0.01 |
| S. creatinine (mg/dL) | 0.98 | 0.24 | 0.96 | 0.26 | -1.57 | 0.067 |

[**Note:** Total Cholesterol (TC), Triglycerides (TG), High-Density cholesterol (HDL-c), Non-High-Density cholesterol (non-HDL-c), Fasting Plasma Glucose (FPG), Post Prandial Plasma Glucose (PPPG), glycosylated haemoglobin (HbA1c), Aspartate transaminase (AST), Alanine transaminase (ALT)]

Lowering of LDL-c values across the patients was observed during the study duration. Figure 2 presents the percentage of participants at each time point, with LDL-c concentrations below 100 mg/dL, 70 mg/dL and 55 mg/dL. The percentage of patients in each level of concentration increased over the time period. The percentage of patients having LDL-c values less than 55 mg/dL increased from the start of the study to 1.43% at 12 weeks and then to 10.0% at 24 weeks. The percentage of patients having

less than 70 mg/dL also increased from the baseline to 8.57% and 19.29% at 12 weeks and 24 weeks respectively.




Figure 2: Percentage composition of patients (%) who achieved LDL-c values of ≤ 100 mg/dl, ≤ 70 mg/dL, and ≤ 55 mg/dL over the study duration

Safety:

No adverse events were observed during the study.

Discussion

The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) released their revised guideline for primary prevention using statins in 2019. The revised goal for LDL-c levels for very high-risk ASCVD has been set at ≤ 55 mg/dL. An updated Systematic Coronary Risk Evaluation (SCORE) system was also introduced. In this new system, the LDL-c criteria for initiating risk-based statin treatment has also been lowered. For SCORE risk of 5 – 10% the level of LDL-c has been reduced to 100 mg/dL, and for $\geq 10\%$ it's been lowered to 70 mg/dL. These changes have emphasized the role of statin therapy as an effective treatment pathway in subjects with relatively low-cholesterol level. [21] In the present study, a gradual decrease by 23.23% and 33.38% was observed in the levels of LDL-c, with a concomitant increase in the percentage of patients with lowered LDL-c values (fig. 1). This lowering of LDL-c along with the lowering of other markers of dyslipidemia like HDL, TC, TG substantiates the efficacy of Bempedoic acid treatment. [22]

Four phase III clinical trials have reported the efficacy of BA in patients with dyslipidemia. These studies are known as the Cholesterol Lowering *via* ETC-1002, an ACL (ATP-citrate lyase)-Inhibiting Regimen (CLEAR) trials. [23] The CLEAR Harmony and CLEAR Wisdom have demonstrated the safety and efficacy of BA with respect to lowering of LDL-c in patients with hypercholesterolemia as an add-on or alternative to currently existing lipid-lowering therapies. In the CLEAR Wisdom trial, the addition of BA significantly lowered LDL-c levels over 12 weeks when compared to placebo (-15.1% vs 2.4% , $p < 0.001$) in patients receiving maximally tolerated statins. Similarly, in the CLEAR Harmony trial, the addition of BA to maximally tolerated statin therapy resulted

|

in significantly lower LDL-c levels from baseline (-12.6%, $p < 0.001$) without an increased incidence of overall adverse events compared to placebo over 52 weeks. These findings collectively suggest that BA holds promise as an adjunct therapy for further reducing LDL-c levels in high-risk patients while maintaining a favorable safety profile. [24,25] In the present study, a similar reduction (23.23%) of LDL-c values was observed at 12 weeks, and a greater reduction (33.38%) was present at the 24 week follow-up. Non-HDL cholesterol values were also reduced by 19.59% and 29.53% at respective points of observation. Comparable values were also observed in the case of TC. However, HDL-c levels displayed an increase, as compared to previous studies.

The literature survey further suggested that by combining the results of the CLEAR Serenity and CLEAR Tranquility trials, it is evident that BA also offers a promising solution for patients who are unable to tolerate statins. In both studies, BA demonstrated significant reductions in LDL-c (-21.4% and -23.5%, respectively), as well as improvements in non-HDL cholesterol, total cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein ($p < 0.001$ for all). Importantly, BA was well tolerated, with similar rates of adverse events compared to placebo. These findings highlight the potential of BA as an effective and safe alternative for lipid-lowering therapy in statin-intolerant patients. [22,26] Recently the results of CLEAR Outcomes demonstrated lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) among statin-intolerant patients treated with BA [BA (11.7%) vs. placebo (13.3%); $p = 0.004$]. [27]

In a fixed dose study with a combination of BA and Ezetimibe, among patients who were already receiving maximally tolerated statin therapy for hypercholesterolemia with a high risk of CVD, statistically significant reduction of LDL-c values was observed (38%, $p < 0.001$), as compared to placebo groups. [26,28] In the present study, reduction in LDL-c values over 12 weeks of observation was also low (23.23%) when compared to previously reported value of BA administration in combination with ezetimibe. [28]

The patients receiving BA treatment in the current study have already been diagnosed with other complications, with diabetes and hypertension being the two most common comorbidities present. BA has been associated with lower incidence of emergence of diabetes mellitus among patients, along with a significant reduction of HbA1c over a period of 1 year. [29] Unlike In the present study HbA1c values did not display any decrease but eventually increased by 4.22% over 24 weeks due to inadequate treatment of uncontrolled diabetes mellitus. This study demonstrated a remarkable absence of adverse events, highlighting the safety profile of the intervention. The findings suggest that the treatment is well-tolerated and devoid of any significant untoward effects. This favorable outcome further supports the feasibility and potential benefits of the intervention in clinical practice.

Conclusion

The present study further establishes the efficacy of BA as an add-on therapy in lowering LDL-c and other markers among patients who have been diagnosed with dyslipidemia or have other co-morbid conditions. A significant reduction of LDL-c values

was observed along with decrease of TG, TC, non-HDL, FPG, PPPG, AST and serum creatinine values across the observation period of 12 weeks and 24 weeks. Similar magnitude of LDL-c reduction has been reported by previous studies globally. In the case of certain markers, where the observed value did not match with previous reports, can be considered to stem from the lower time frame considered for the present investigation. However, these observations highlighted the importance of long-term clinical observations on BA efficacy. The BEST registry is aimed to fulfill this need precisely. Further investigations on BA efficacy and safety in patients with a high risk of CVD is thus warranted.

References

1. Cardiovascular diseases (CVDs) by World Health Organization (WHO). Available from: <https://www.who.int/health-topics/cardiovascular-diseases>. Accessed on April 30, 2023, 3:00 pm IST.
2. Mendis S, Puska P, Norrving B, Organization WH, Federation WH, Organization WS: Global atlas on cardiovascular disease prevention and control / edited by: Shanthi Mendis ... [et al.]. 2011, Published by the World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization.
3. Pol T, Held C, Westerbergh J, et al.: Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. *J Am Heart Assoc.* 2018, 7:e007444. 10.1161/JAHA.117.007444
4. Carroll MD, Fryar CD, Kit BK: Total and High-density Lipoprotein Cholesterol in Adults: United States, 2011-2014. *NCHS Data Brief.* 2015, 1–8.
5. Sadananda SN, Foo JN, Toh MT, et al.: Targeted next-generation sequencing to diagnose disorders of HDL cholesterol. *J Lipid Res.* 2015, 56:1993–2001. 10.1194/jlr.P058891

6. Schwartz GG, Olsson AG, Abt M, et al.: Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. *N Engl J Med.* 2012, 367:2089–99. 10.1056/NEJMoa1206797
7. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. *N Engl J Med.* 2004, 350:1495–504. 10.1056/NEJMoa040583
8. Evolocumab in Patients with Cardiovascular Disease. *N Engl J Med.* 2017, 377:785–8. 10.1056/NEJMc1708587
9. Amarenco P, Kim JS, Labreuche J, et al.: A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. *N Engl J Med.* 2020, 382:9–19. 10.1056/NEJMoa1910355
10. Ouchi Y, Sasaki J, Arai H, et al.: Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. *Circulation.* 2019, 140:992–1003. 10.1161/CIRCULATIONAHA.118.039415
11. Grundy SM, Stone NJ, Bailey AL, et al.: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* 2019, 139:. 10.1161/CIR.0000000000000625
12. Ray KK, Ginsberg HN, Davidson MH, et al.: Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. *Circulation.* 2016, 134:1931–43. 10.1161/CIRCULATIONAHA.116.024604
13. Wang Q, Liang C: Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. *J Cardiovasc Pharmacol.* 2020, 76:658–70. 10.1097/FJC.0000000000000914
14. Bytyçi I, Penson PE, Mikhailidis DP, et al.: Prevalence of statin intolerance: a meta-analysis. *Eur Heart J.* 2022, 43:3213–23. 10.1093/eurheartj/ehac015
15. Ray KK, Molemans B, Schoonen WM, et al.: EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. *Eur J Prev Cardiol.* 2021, 28:1279–89. 10.1093/eurjpc/zwaa047
16. Nexletol (Bempedoic Acid) Prescribing Information. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf.
17. Niman S, Rana K, Reid J, Sheikh-Ali M, Lewis T, Choksi RR, Goldfaden RF: A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of

Hypercholesterolemia. *Am J Cardiovasc Drugs*. 2020, 20:535–48. 10.1007/s40256-020-00399-w

18. Pinkosky SL, Filippov S, Srivastava RAK, et al.: AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. *J Lipid Res*. 2013, 54:134–51. 10.1194/jlr.M030528
19. Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ: Role of Bempedoic Acid in Clinical Practice. *Cardiovasc Drugs Ther*. 2021, 35:853–64. 10.1007/s10557-021-07147-5
20. François Mach and others, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), *European Heart Journal*, Volume 41, Issue 1, 1 January 2020, Pages 111–188.
21. Mortensen MB, Nordestgaard BG: 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease. *Eur Heart J*. 2020, 41:3005–15. 10.1093/eurheartj/ehaa150
22. Laufs U, Banach M, Mancini GBJ, et al.: Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. *J Am Heart Assoc*. 2019, 8:e011662. 10.1161/JAHA.118.011662
23. Agarwala A, Quispe R, Goldberg AC, Michos ED: Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside. *Drug Des Devel Ther*. 2021, 15:1955–63. 10.2147/DDDT.S251865
24. Goldberg AC, Leiter LA, Stroes ESG, et al.: Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. *JAMA*. 2019, 322:1780–8. 10.1001/jama.2019.16585
25. Ballantyne CM, Banach M, Bays HE, et al.: Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). *Am J Cardiol*. 2022, 174:1–11. 10.1016/j.amjcard.2022.03.020
26. Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA: Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. *Atherosclerosis*. 2018, 277:195–203. 10.1016/j.atherosclerosis.2018.06.002

27. Nissen SE, Lincoff AM, Brennan D, et al.: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. *N Engl J Med.* 2023, 388:1353–64. 10.1056/NEJMoa2215024
28. Ballantyne CM, Laufs U, Ray KK, et al.: Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. *Eur J Prev Cardiol.* 2020, 27:593–603. 10.1177/2047487319864671
29. Leiter LA, Banach M, Catapano AL, et al.: Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. *Diabetes Obes Metab.* 2022, 24:868–80. 10.1111/dom.14645